Molecular and Cellular Pharmacology, Vol 10, No 3 (2018)

FDA Approves First Treatment for Lambert-Eaton Myasthenic Syndrome, a Rare Autoimmune Disorder

Abstract

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder that affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. This is the first FDA approval of a treatment for….

Full Text: PDF